Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Vor Biopharma Inc. (NYSE:VOR) have earned a consensus rating of “Buy” from the seven analysts that are presently covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have covered the stock in the last year is $11.36.

Several brokerages recently weighed in on VOR. HC Wainwright reiterated a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th. JMP Securities reiterated a “market outperform” rating and set a $12.00 price target on shares of Vor Biopharma in a report on Tuesday, December 10th. Robert W. Baird reduced their price objective on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Vor Biopharma in a research report on Monday, December 9th.

Vor Biopharma Trading Up 3.7 %

Shares of VOR stock opened at $1.39 on Wednesday. Vor Biopharma has a twelve month low of $0.63 and a twelve month high of $2.43. The stock has a market cap of $95.46 million, a price-to-earnings ratio of -0.84 and a beta of -0.51. The company’s 50-day moving average price is $1.17 and its 200-day moving average price is $0.96.

Vor Biopharma (NYSE:VOR) last posted its earnings results on Thursday, November 7th. The company reported ($0.40) earnings per share for the quarter, meeting the consensus estimate of ($0.40). As a group, equities research analysts predict that Vor Biopharma will post -1.42 EPS for the current year.

Hedge Funds Weigh In On Vor Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of VOR. Renaissance Technologies LLC lifted its position in shares of Vor Biopharma by 48.0% during the second quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock worth $495,000 after purchasing an additional 160,642 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Vor Biopharma during the 2nd quarter worth approximately $53,000. Exchange Traded Concepts LLC lifted its holdings in Vor Biopharma by 40.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock worth $116,000 after buying an additional 48,017 shares in the last quarter. Finally, Rosalind Advisors Inc. purchased a new position in Vor Biopharma in the 3rd quarter valued at approximately $54,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.